Effects of sodium‐glucose cotransporter‐2 inhibitors in myocardial infarction patients: A systematic review and meta‐analysis
Authors' conclusion
In post-MI patients, we first found that SGLT2 inhibitors significantly lowered the risk of HHF, combined CV death or HHF, all-cause death, MACE, recurrent MI, severe arrhythmias and renal injury. Additionally, SGLT2 inhibitors improved LVEF and LVEDV.
Study context
- Population
- Patients after myocardial infarction (MI)
- Participants
- 22,370 patients13 studies
- Comparison
- SGLT2 inhibitors in post-MI patients
- Outcome
- Primary outcomes: Hospitalization for heart failure (HHF), cardiovascular (CV) death, composite of HHF or CV death, all-cause death, major cardiovascular events (MACE), recurrent MI, severe arrhythmia, renal injury and stroke
Pooled result
As reported in the abstract
Primary outcomes
SGLT2 inhibitorsRelative risk (95% CI)P value
HHF
0.69(0.61–0.78)
P < 0.001HHF or CV death
0.87(0.77–0.99)
P = 0.028All-cause mortality
0.82(0.73–0.93)
P = 0.002MACE
0.68(0.53–0.88)
P = 0.004Recurrent MI
0.81(0.69–0.94)
P = 0.007Severe arrhythmia
0.54(0.34–0.85)
P = 0.009Renal injury
0.68(0.53–0.87)
P = 0.002Further pooled results
Left ventricular ejection fraction (LVEF) improvement
| MD (%) (95% CI) | P value | ||
|---|---|---|---|
| SGLT2 inhibitorsGreater improvement with SGLT2 inhibitors | 3.96 (2.52–5.40) | P < 0.001 | |
| −50510Difference, % (linear scale) |
Left ventricular end-diastolic volume (LVEDV) improvement
| MD (mL) (95% CI) | P value | ||
|---|---|---|---|
| SGLT2 inhibitorsGreater improvement with SGLT2 inhibitors | −5.52 (−10.21 to −0.83) | P = 0.021 | |
| −15−10−505Difference, mL (linear scale) |
Original publication
Effects of sodium‐glucose cotransporter‐2 inhibitors in myocardial infarction patients: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 18 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →